We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.24B
AUM Growth
+$171M
Cap. Flow
+$215M
Cap. Flow %
2.98%
Top 10 Hldgs %
34.84%
Holding
226
New
18
Increased
74
Reduced
41
Closed
9

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$49.6M
2
EXAS
Exact Sciences
EXAS
+$26.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.9M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$24.6M
5
MTEM
Molecular Templates, Inc.
MTEM
+$18.3M

Top Sells

Rank Stock Value
1
HALO icon
Halozyme
HALO
+$35.1M
2
PACB icon
Pacific Biosciences
PACB
+$25.7M
3
EVH icon
Evolent Health
EVH
+$20.6M
4
AKCA
Akcea Therapeutics Inc
AKCA
+$15.9M
5
MDT icon
Medtronic
MDT
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
2 Industrials 0.6%
3 Technology 0.53%
4 Communication Services 0.41%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$414M 5.71%
8,716,270
+466,397
+6% +$25.9M
NBIX icon
2
Neurocrine Biosciences
NBIX
$17.2B
$317M 4.38%
3,297,451
+86,551
+3% +$10M
INCY icon
3
Incyte
INCY
$23.4B
$294M 4.07%
3,279,450
-13,150
-0.4% -$1.27M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$261M 3.61%
960,600
-22,000
-2% -$6.07M
ARGX icon
5
argenx
ARGX
$53.8B
$252M 3.48%
959,016
+5,000
+0.5% +$1.2M
MRNA icon
6
Moderna
MRNA
$24.5B
$236M 3.27%
3,341,950
-3,000
-0.1% -$209K
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$35.7B
$227M 3.14%
1,559,805
-50,260
-3% -$7.14M
ESPR
8
DELISTED
Esperion Therapeutics
ESPR
$203M 2.81%
5,465,715
+162,580
+3% +$6.44M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$163M 2.25%
1,421,128
+8,300
+0.6% +$895K
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$154M 2.13%
1,128,400
-79,913
-7% -$8.5M
AGIO icon
11
Agios Pharmaceuticals
AGIO
$2.36B
$145M 2.01%
4,151,002
+127,429
+3% +$5.59M
HALO icon
12
Halozyme
HALO
$9.23B
$144M 1.99%
5,469,131
-1,261,421
-19% -$35.1M
ABT icon
13
Abbott
ABT
$175B
$140M 1.94%
1,288,285
+4,013
+0.3% +$407K
MGNX icon
14
MacroGenics
MGNX
$285M
$133M 1.84%
5,282,188
+280,072
+6% +$7.65M
ISRG icon
15
Intuitive Surgical
ISRG
$122B
$109M 1.5%
459,552
-9,147
-2% -$2.05M
UNH icon
16
UnitedHealth
UNH
$387B
$101M 1.4%
324,053
+17,417
+6% +$5.35M
HUM icon
17
Humana
HUM
$48B
$101M 1.4%
243,996
+8,356
+4% +$3.36M
BMY icon
18
Bristol-Myers Squibb
BMY
$124B
$99.2M 1.37%
1,645,912
+33,800
+2% +$2.03M
DHR icon
19
Danaher
DHR
$144B
$97.6M 1.35%
511,417
+1,975
+0.4% +$351K
SAGE
20
DELISTED
Sage Therapeutics
SAGE
$96.5M 1.33%
1,579,504
+164,000
+12% +$8.31M
ELV icon
21
Elevance Health
ELV
$80.9B
$93.8M 1.3%
349,123
+39,098
+13% +$10.5M
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$91.9M 1.27%
3,579,919
-200,000
-5% -$4.56M
FATE icon
23
Fate Therapeutics
FATE
$324M
$88.6M 1.22%
2,217,500
+256,100
+13% +$8.94M
MDT icon
24
Medtronic
MDT
$106B
$86.4M 1.19%
831,450
-146,073
-15% -$14.7M
RDUS
25
DELISTED
Radius Health, Inc.
RDUS
$84.3M 1.16%
7,431,414
+424,029
+6% +$5.24M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2020 Portfolio in Review

As of Q3 2020, Bellevue Group held 226 positions worth $7.24B, up 2.4% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q3 2020 filing shows 18 new, 74 increased, 41 reduced and 9 closed positions. Its largest new stake was Relay Therapeutics: 1,300,000 shares worth $55.4M. The largest sale was Halozyme, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2020 buy was Relay Therapeutics: 1,300,000 shares worth $55.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2020, an estimated $25.9M increase.
  • Bellevue Group's biggest Q3 2020 reduction was Halozyme, cutting an estimated $35.1M.
  • Bellevue Group fully exited BioMarin Pharmaceuticals in Q3 2020, selling an estimated $9.48M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.24B portfolio in Q3 2020.
  • Bellevue Group opened 18 new positions and closed 9 in Q3 2020.
  • Bellevue Group's portfolio value rose 2.4% quarter-over-quarter to $7.24B.

Based on Bellevue Group's 13F filing for Q3 2020, filed 16 Nov 2020.